Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 321

1.

Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study.

Latourte A, Ea HK, Frazier A, Blanchard A, Lioté F, Marotte H, Bardin T, Richette P.

Ann Rheum Dis. 2020 Mar 25. pii: annrheumdis-2020-217188. doi: 10.1136/annrheumdis-2020-217188. [Epub ahead of print] No abstract available.

PMID:
32213498
3.

Chondrocalcinosis of the Knee and the Risk of Osteoarthritis Progression: Data From the Knee and Hip Osteoarthritis Long-term Assessment Cohort.

Latourte A, Rat AC, Ngueyon Sime W, Ea HK, Bardin T, Mazières B, Roux C, Guillemin F, Richette P.

Arthritis Rheumatol. 2019 Dec 5. doi: 10.1002/art.41186. [Epub ahead of print]

PMID:
31804010
4.

Shoulder adhesive capsulitis: diagnostic value of active and passive range of motion with volume of gleno-humeral capsule as a reference.

James-Belin E, Lasbleiz S, Haddad A, Morchoisne O, Ostertag A, Yelnik A, Laredo JD, Bardin T, Orcel P, Richette P, Beaudreuil J.

Eur J Phys Rehabil Med. 2019 Nov 18. doi: 10.23736/S1973-9087.19.05890-8. [Epub ahead of print]

5.

Iterative percutaneous needle aponeurotomy for Dupuytren's disease: Functional outcome at 5-year follow-up.

Ferrari M, Lellouche H, Roulot E, Yelnik A, Bardin T, Orcel P, Richette P, Beaudreuil J.

Joint Bone Spine. 2019 Oct 24. pii: S1297-319X(19)30150-2. doi: 10.1016/j.jbspin.2019.10.003. [Epub ahead of print] No abstract available.

PMID:
31669810
6.

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.

Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, Gaffo AL, Rosenthal A, Tausche AK, Reginato A, Manger B, Sciré C, Pineda C, van Durme C, Lin CT, Yin C, Albert DA, Biernat-Kaluza E, Roddy E, Pascual E, Becce F, Perez-Ruiz F, Sivera F, Lioté F, Schett G, Nuki G, Filippou G, McCarthy G, da Rocha Castelar Pinheiro G, Ea HK, Tupinambá HA, Yamanaka H, Choi HK, Mackay J, ODell JR, Vázquez Mellado J, Singh JA, Fitzgerald JD, Jacobsson LTH, Joosten L, Harrold LR, Stamp L, Andrés M, Gutierrez M, Kuwabara M, Dehlin M, Janssen M, Doherty M, Hershfield MS, Pillinger M, Edwards NL, Schlesinger N, Kumar N, Slot O, Ottaviani S, Richette P, MacMullan PA, Chapman PT, Lipsky PE, Robinson P, Khanna PP, Gancheva RN, Grainger R, Johnson RJ, Te Kampe R, Keenan RT, Tedeschi SK, Kim S, Choi SJ, Fields TR, Bardin T, Uhlig T, Jansen T, Merriman T, Pascart T, Neogi T, Klück V, Louthrenoo W, Dalbeth N.

Ann Rheum Dis. 2019 Nov;78(11):1592-1600. doi: 10.1136/annrheumdis-2019-215933. Epub 2019 Sep 9.

PMID:
31501138
7.

Defining remission in patients with gout.

Bardin T, Richette P.

Nat Rev Rheumatol. 2019 Sep;15(9):516-517. doi: 10.1038/s41584-019-0280-0. No abstract available.

PMID:
31363189
8.

Monosodium urate deposition in the articular cartilage and meniscus can mimic chondrocalcinosis.

Bousson V, Bardin T, Zeitoun D, Sverzut JM, Ea HK.

Joint Bone Spine. 2020 Jan;87(1):95-96. doi: 10.1016/j.jbspin.2019.06.014. Epub 2019 Jul 17. No abstract available.

PMID:
31325593
9.

2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout.

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, Coyfish M, Guillo S, Jansen T, Janssens H, Lioté F, Mallen CD, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell A, So AK, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T.

Ann Rheum Dis. 2020 Jan;79(1):31-38. doi: 10.1136/annrheumdis-2019-215315. Epub 2019 Jun 5.

PMID:
31167758
10.

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.

Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X; French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries.

BMJ. 2019 Jan 24;364:l67. doi: 10.1136/bmj.l67.

11.

The role of febuxostat in gout.

Bardin T, Richette P.

Curr Opin Rheumatol. 2019 Mar;31(2):152-158. doi: 10.1097/BOR.0000000000000573. Review.

PMID:
30601228
12.

Spinal involvement with calcium pyrophosphate deposition disease in an academic rheumatology center: A series of 37 patients.

Moshrif A, Laredo JD, Bassiouni H, Abdelkareem M, Richette P, Rigon MR, Bardin T.

Semin Arthritis Rheum. 2019 Jun;48(6):1113-1126. doi: 10.1016/j.semarthrit.2018.10.009. Epub 2018 Oct 14.

PMID:
30415946
13.

Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study.

Ebstein E, Forien M, Norkuviene E, Richette P, Mouterde G, Daien C, Ea HK, Brière C, Lioté F, Petraitis M, Bardin T, Ora J, Dieudé P, Ottaviani S.

Rheumatology (Oxford). 2019 Mar 1;58(3):410-417. doi: 10.1093/rheumatology/key303.

PMID:
30285127
14.

Renal medulla in severe gout: typical findings on ultrasonography and dual-energy CT study in two patients.

Bardin T, Tran KM, Nguyen QD, Sarfati M, Richette P, Vo NT, Bousson V, Correas JM.

Ann Rheum Dis. 2019 Mar;78(3):433-434. doi: 10.1136/annrheumdis-2018-214174. Epub 2018 Sep 29. No abstract available.

PMID:
30269050
15.

Tendon thickening in dialysis-related joint arthritis is due to amyloid deposits at the surface of the tendon.

Sigaux J, Abdelkefi I, Bardin T, Laredo JD, Ea HK, UreñaTorres P, Cohen-Solal M.

Joint Bone Spine. 2019 Mar;86(2):233-238. doi: 10.1016/j.jbspin.2018.08.005. Epub 2018 Sep 19.

PMID:
30243785
16.

Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout.

Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andrés M, Vargas-Santos AB, Roddy E, Pascart T, Lin CT, Perez-Ruiz F, Tedeschi SK, Kim SC, Harrold LR, McCarthy G, Kumar N, Chapman PT, Tausche AK, Vazquez-Mellado J, Gutierrez M, da Rocha Castelar-Pinheiro G, Richette P, Pascual E, Fisher MC, Burgos-Vargas R, Robinson PC, Singh JA, Jansen TL, Saag KG, Slot O, Uhlig T, Solomon DH, Keenan RT, Scire CA, Biernat-Kaluza E, Dehlin M, Nuki G, Schlesinger N, Janssen M, Stamp LK, Sivera F, Reginato AM, Jacobsson L, Lioté F, Ea HK, Rosenthal A, Bardin T, Choi HK, Hershfield MS, Czegley C, Choi SJ, Dalbeth N.

Arthritis Care Res (Hoboken). 2019 Mar;71(3):427-434. doi: 10.1002/acr.23607.

17.

Accuracy of the HumaSensplus point-of-care uric acid meter using capillary blood obtained by fingertip puncture.

Fabre S, Clerson P, Launay JM, Gautier JF, Vidal-Trecan T, Riveline JP, Platt A, Abrahamsson A, Miner JN, Hughes G, Richette P, Bardin T.

Arthritis Res Ther. 2018 May 2;20(1):78. doi: 10.1186/s13075-018-1585-0.

18.

Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study.

Loustau C, Rosine N, Forien M, Ottaviani S, Juge PA, Lioté F, Bardin T, Richette P, Dieudé P, Richez C, Bannwarth B, Schaeverbeke T, Ea HK, Truchetet ME.

Joint Bone Spine. 2018 Dec;85(6):755-760. doi: 10.1016/j.jbspin.2018.03.015. Epub 2018 Apr 11.

PMID:
29654950
19.

Reproducibility of sub-acromial impingement tests, including a new clinical manoeuver.

Ferenczi A, Ostertag A, Lasbleiz S, Petrover D, Yelnik A, Richette P, Bardin T, Orcel P, Beaudreuil J.

Ann Phys Rehabil Med. 2018 May;61(3):151-155. doi: 10.1016/j.rehab.2018.01.005. Epub 2018 Feb 13.

20.

Uric acid and cognitive decline: a double-edge sword?

Latourte A, Bardin T, Richette P.

Curr Opin Rheumatol. 2018 Mar;30(2):183-187. doi: 10.1097/BOR.0000000000000472.

PMID:
29389776
21.

Novel uricosurics.

Bardin T, Richette P.

Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i42-i46. doi: 10.1093/rheumatology/kex433. Review.

PMID:
29272511
22.

Cardiac and renal protective effects of urate-lowering therapy.

Richette P, Latourte A, Bardin T.

Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i47-i50. doi: 10.1093/rheumatology/kex432. Review.

PMID:
29272510
23.

Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry.

Nourisson C, Soubrier M, Mulliez A, Baillet A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Schaeverbeke T, Sibilia J, Vittecoq O, Ravaud P, Gottenberg JE, Mariette X, Tournadre A.

RMD Open. 2017 Nov 1;3(2):e000515. doi: 10.1136/rmdopen-2017-000515. eCollection 2017.

24.

Response to: 'Uric acid and incident dementia: a population-based cohort study' by Lee and Song.

Latourte A, Soumaré A, Bardin T, Debette S, Richette P.

Ann Rheum Dis. 2018 Sep;77(9):e63. doi: 10.1136/annrheumdis-2017-212582. Epub 2017 Nov 13. No abstract available.

PMID:
29133476
25.

Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.

Latourte A, Bardin T, Clerson P, Ea HK, Flipo RM, Richette P.

Arthritis Care Res (Hoboken). 2018 Jun;70(6):918-924. doi: 10.1002/acr.23347. Epub 2018 Mar 23.

26.

Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN).

Dalbeth N, Bardin T, Doherty M, Lioté F, Richette P, Saag KG, So AK, Stamp LK, Choi HK, Terkeltaub R.

Nat Rev Rheumatol. 2017 Sep;13(9):561-568. doi: 10.1038/nrrheum.2017.126. Epub 2017 Aug 10. Review.

PMID:
28794514
27.

Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study.

Latourte A, Soumaré A, Bardin T, Perez-Ruiz F, Debette S, Richette P.

Ann Rheum Dis. 2018 Mar;77(3):328-335. doi: 10.1136/annrheumdis-2016-210767. Epub 2017 Jul 28.

PMID:
28754803
28.

Gout: An old disease in new perspective - A review.

Ragab G, Elshahaly M, Bardin T.

J Adv Res. 2017 Sep;8(5):495-511. doi: 10.1016/j.jare.2017.04.008. Epub 2017 May 10. Review.

29.

Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options.

Bardin T, Richette P.

BMC Med. 2017 Jul 3;15(1):123. doi: 10.1186/s12916-017-0890-9. Review.

30.

SUA levels should not be maintained <3 mg/dL for several years. Response to 'EULAR gout treatment guidelines by Richette et al: uric acid and neurocognition by Singh et al'.

Richette P, Doherty M, Pascual E, Bardin T.

Ann Rheum Dis. 2018 Apr;77(4):e21. doi: 10.1136/annrheumdis-2017-211423. Epub 2017 Apr 17. No abstract available.

PMID:
28416517
31.

Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE.

Terreaux W, Masson C, Eschard JP, Bardin T, Constantin A, Le Dantec L, Marcelli C, Perdriger A, Scotto Di Fazano C, Wendling D, Sibilia J, Morel J, Salmon JH.

Joint Bone Spine. 2018 Jan;85(1):53-57. doi: 10.1016/j.jbspin.2017.01.002. Epub 2017 Jan 20.

PMID:
28115268
32.

Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: Report of four cases.

Mageau A, Guigonis V, Ratzimbasafy V, Bardin T, Richette P, Urena P, Ea HK.

Joint Bone Spine. 2017 May;84(3):341-344. doi: 10.1016/j.jbspin.2016.10.009. Epub 2016 Dec 7.

PMID:
27955821
33.

Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers.

Juge PA, Truchetet ME, Pillebout E, Ottaviani S, Vigneau C, Loustau C, Cornec D, Pascart T, Snanoudj R, Bailly F, Cornec-Le Gall E, Schaeverbeke T, Saraux A, Dieudé P, Flipo RM, Richette P, Lioté F, Bardin T, Chalès G, Ea HK.

Joint Bone Spine. 2017 Oct;84(5):595-598. doi: 10.1016/j.jbspin.2016.09.020. Epub 2016 Nov 4.

PMID:
27825577
34.

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).

Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, So A.

Ann Rheum Dis. 2017 May;76(5):811-820. doi: 10.1136/annrheumdis-2016-209213. Epub 2016 Nov 7.

35.

Response: Renal dosing of allopurinol results in suboptimal gout care by T Neogi et al.

Richette P, Doherty M, Pascual E, Bardin T.

Ann Rheum Dis. 2017 Jan;76(1):e2. doi: 10.1136/annrheumdis-2016-210356. Epub 2016 Nov 3. No abstract available.

PMID:
27811145
36.

Treat-to-target (T2T) recommendations for gout.

Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, Engel B, Flader C, Kay J, Matsuoka M, Perez-Ruiz F, da Rocha Castelar-Pinheiro G, Saag K, So A, Vazquez Mellado J, Weisman M, Westhoff TH, Yamanaka H, Braun J.

Ann Rheum Dis. 2017 Apr;76(4):632-638. doi: 10.1136/annrheumdis-2016-209467. Epub 2016 Sep 22.

PMID:
27658678
37.

2016 updated EULAR evidence-based recommendations for the management of gout.

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T.

Ann Rheum Dis. 2017 Jan;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25. Review.

PMID:
27457514
38.

Probing The Relation Between Vitamin D Deficiency and Progression of Medial Femoro-tibial Osteoarthitis of the Knee.

Bassiouni H, Aly H, Zaky K, Abaza N, Bardin T.

Curr Rheumatol Rev. 2017;13(1):65-71. doi: 10.2174/1573397112666160404124532.

PMID:
27041085
39.

Weight Loss, Xanthine Oxidase, and Serum Urate Levels: A Prospective Longitudinal Study of Obese Patients.

Richette P, Poitou C, Manivet P, Denis J, Bouillot JL, Clément K, Oppert JM, Bardin T.

Arthritis Care Res (Hoboken). 2016 Jul;68(7):1036-42. doi: 10.1002/acr.22798.

40.

Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.

Lahaye C, Soubrier M, Mulliez A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Le Loët X, Shaeverbeke T, Ravaud P, Mariette X, Gottenberg JE; French Society of Rheumatology.

Rheumatology (Oxford). 2016 May;55(5):874-82. doi: 10.1093/rheumatology/kev437. Epub 2016 Jan 27.

PMID:
26822072
41.

Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).

Cooper C, Bardin T, Brandi ML, Cacoub P, Caminis J, Civitelli R, Cutolo M, Dere W, Devogelaer JP, Diez-Perez A, Einhorn TA, Emonts P, Ethgen O, Kanis JA, Kaufman JM, Kvien TK, Lems WF, McCloskey E, Miossec P, Reiter S, Ringe J, Rizzoli R, Saag K, Reginster JY.

Aging Clin Exp Res. 2016 Feb;28(1):1-16. doi: 10.1007/s40520-015-0522-1. Epub 2016 Jan 8. Review.

PMID:
26746234
42.

Characterization of copy number variants for CCL3L1 gene in rheumatoid arthritis for French trio families and Tunisian cases and controls.

Ben Kilani MS, Achour Y, Perea J, Cornelis F, Bardin T, Chaudru V, Maalej A, Petit-Teixeira E.

Clin Rheumatol. 2016 Aug;35(8):1917-1922. doi: 10.1007/s10067-015-3156-y. Epub 2016 Jan 4.

PMID:
26728148
43.

Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence.

Bardin T.

Joint Bone Spine. 2015 Oct;82 Suppl 1:eS9-16. doi: 10.1016/S1297-319X(15)30003-8. Review.

PMID:
26717801
44.

The Way Forward: Practical Clinical Considerations for the Use of Canakinumab in Patients With Difficult-to-Treat Gouty Arthritis.

Bardin T, van de Laar MA.

Joint Bone Spine. 2015 Oct;82 Suppl 1:eS30-2. doi: 10.1016/S1297-319X(15)30005-1.

PMID:
26717800
45.

The Human and Economic Burden of Difficult-to-Treat Gouty Arthritis.

Bardin T, Voshaar MA, van de Laar MA.

Joint Bone Spine. 2015 Oct;82 Suppl 1:eS2-8. doi: 10.1016/S1297-319X(15)30002-6.

PMID:
26717799
46.

Foreword.

Bardin T, van de Laar MA.

Joint Bone Spine. 2015 Oct;82 Suppl 1:eS1. doi: 10.1016/S1297-319X(15)30001-4. No abstract available.

PMID:
26717797
47.

Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment.

Bardin T, Chalès G, Pascart T, Flipo RM, Korng Ea H, Roujeau JC, Delayen A, Clerson P.

Joint Bone Spine. 2016 May;83(3):314-7. doi: 10.1016/j.jbspin.2015.07.011. Epub 2015 Dec 18.

PMID:
26709250
48.

Sodium thiosulfate is effective in calcific uremic arteriolopathy complicating chronic hemodialysis.

Malbos S, Ureña-Torres P, Bardin T, Ea HK.

Joint Bone Spine. 2016 Jan;83(1):89-92. doi: 10.1016/j.jbspin.2015.03.007. Epub 2015 Oct 19.

PMID:
26494591
49.

Prevalence of Gout in the Adult Population of France.

Bardin T, Bouée S, Clerson P, Chalès G, Flipo RM, Lioté F, Perez V, Poiraud T, Schaeverbeke T, Richette P.

Arthritis Care Res (Hoboken). 2016 Feb;68(2):261-6. doi: 10.1002/acr.22660.

50.

Serum uric acid and the risk of cardiovascular and renal disease.

Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, Manolis AJ, Perez-Ruiz F, Mancia G.

J Hypertens. 2015 Sep;33(9):1729-41; discussion 1741. doi: 10.1097/HJH.0000000000000701. Review.

PMID:
26136207

Supplemental Content

Loading ...
Support Center